CUTISS

CUTISSCUTISS
C

CUTISS

Pioneering bio-engineered skin grafts for severe burns and chronic wounds.

Website
DR 442014ActiveZurich, Switzerland
Rate
Advertise here

About

CUTISS is a late-stage clinical TechBio company revolutionizing skin surgery with denovoSkin™, a first-in-class personalized tissue therapy for on-demand production of living human skin. This technology is designed for patients requiring skin surgery, from severe burns to reconstructive and aesthetic applications, offering a safe and effective alternative to the standard of care. CUTISS also leverages its scalable, automated production platform for advancements in regenerative medicine, space health research, and industrial bioengineered tissue applications.
Frequently asked

What does CUTISS do?

CUTISS is a late-stage clinical TechBio company revolutionizing skin surgery with denovoSkin™, a first-in-class personalized tissue therapy for on-demand production of living human skin. This technology is designed for patients requiring skin surgery, from severe burns to reconstructive and aesthetic applications, offering a safe and effective alternative to the standard of care. CUTISS also leverages its scalable, automated production platform for advancements in regenerative medicine, space he…

What is CUTISS's valuation?

StartupHub estimates CUTISS's effective valuation at $526.6M (range $337.6M to $810.2M, 18% confidence), based on comparable companies in the sector.

How much funding has CUTISS raised?

CUTISS has raised a total of $135M in funding. The most recent round on record is Series C.

Where is CUTISS headquartered?

CUTISS is headquartered in Zurich, Switzerland.

When was CUTISS founded?

CUTISS was founded in 2014.

What industry does CUTISS operate in?

CUTISS operates in MedTech, HealthTech, Biotech, Regenerative Medicine, Tissue Engineering, Medical Devices.

Comments

No comments yet. Be the first to share your take.